Third Time’s Not The Charm For King’s Pursuit of Alpharma
Executive Summary
As King Pharmaceuticals tries to move past the hit from the entry of generic competition for Altace and overall lackluster second quarter sales figures, the firm has embarked on a plan to become a powerhouse specialty therapeutic pain company, and a central piece of that plan is the acquisition of Alpharma. But Alpharma will have none of it
You may also be interested in...
King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle
King Pharmaceuticals believes the FDA review of its abuse-resistant painkiller Embeda is "substantially complete," and that the company will be able to launch the drug in 2009, CEO Brian Markison assured investors during an earnings call Feb. 26
King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle
King Pharmaceuticals believes the FDA review of its abuse-resistant painkiller Embeda is "substantially complete," and that the company will be able to launch the drug in 2009, CEO Brian Markison assured investors during an earnings call Feb. 26
King Confident Of Embeda Okay In 2009
Despite a recent, significant downsizing, King is ready to launch the abuse-resistant drug.